Mercury Biopharmaceutical Corporation (TPEX: 6932)
15.60
+0.40 (2.63%)
Sep 10, 2024, 2:46 PM CST
Mercury Biopharmaceutical Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
Cash & Equivalents | 166.09 | 44.29 | 31.94 | 2.56 | 0.09 | 0.15 |
Short-Term Investments | 98.8 | 284.78 | 108.7 | - | - | - |
Cash & Short-Term Investments | 264.89 | 329.07 | 140.64 | 2.56 | 0.09 | 0.15 |
Cash Growth | -25.71% | 133.99% | 5391.45% | 2877.91% | -43.79% | - |
Other Receivables | 3.99 | 3.76 | 2.46 | - | - | - |
Receivables | 3.99 | 3.76 | 2.46 | - | - | - |
Prepaid Expenses | 6.39 | 6.54 | 2.64 | - | 0.01 | 0 |
Other Current Assets | 0.24 | 0.55 | - | 1.37 | - | - |
Total Current Assets | 275.51 | 339.93 | 145.73 | 3.93 | 0.1 | 0.16 |
Property, Plant & Equipment | 88.61 | 79.94 | 75.15 | 8.46 | - | - |
Other Intangible Assets | 3.14 | 2.71 | 0.5 | 0.49 | - | - |
Other Long-Term Assets | 11.55 | 15.5 | 8.55 | 0.51 | - | - |
Total Assets | 378.81 | 438.08 | 229.93 | 13.38 | 0.1 | 0.16 |
Accrued Expenses | 2.32 | 5.06 | 4.61 | 0.66 | 0.01 | - |
Short-Term Debt | - | - | - | - | 0.3 | 0.15 |
Current Portion of Leases | 0.27 | 0.68 | 1.05 | 0.79 | - | - |
Current Unearned Revenue | 5.73 | 0.44 | - | - | - | - |
Other Current Liabilities | 4.9 | 1.87 | 1.57 | 0.26 | - | 0.01 |
Total Current Liabilities | 13.4 | 8.05 | 7.23 | 1.7 | 0.31 | 0.16 |
Long-Term Debt | 41.43 | 41.6 | 41.6 | - | - | - |
Long-Term Leases | 0.08 | 0.07 | 0.77 | 1.22 | - | - |
Total Liabilities | 54.9 | 49.72 | 49.6 | 2.93 | 0.31 | 0.16 |
Common Stock | 104.36 | 103.99 | 100.87 | 15.4 | 0.2 | 0.2 |
Additional Paid-In Capital | 281.86 | 328.17 | 110.72 | 0.37 | - | - |
Retained Earnings | -18.31 | -43.82 | -31.25 | -5.31 | -0.41 | -0.2 |
Comprensive Income & Other | 3.04 | 0.01 | - | - | - | - |
Shareholders' Equity | 323.91 | 388.35 | 180.33 | 10.46 | -0.21 | 0 |
Total Liabilities & Equity | 378.81 | 438.08 | 229.93 | 13.38 | 0.1 | 0.16 |
Total Debt | 41.95 | 42.35 | 43.42 | 2.01 | 0.3 | 0.15 |
Net Cash (Debt) | 222.94 | 286.73 | 97.21 | 0.55 | -0.21 | 0 |
Net Cash Growth | -28.93% | 194.95% | 17575.09% | - | - | - |
Net Cash Per Share | 0.54 | 0.70 | 0.26 | 0.00 | -0.00 | - |
Filing Date Shares Outstanding | 414.5 | 415.96 | 403.46 | 403.46 | 104 | - |
Total Common Shares Outstanding | 414.5 | 415.96 | 403.46 | 307.94 | 104 | - |
Working Capital | 262.12 | 331.88 | 138.5 | 2.22 | -0.21 | 0 |
Book Value Per Share | 0.78 | 0.93 | 0.45 | 0.03 | -0.00 | - |
Tangible Book Value | 320.77 | 385.65 | 179.83 | 9.97 | -0.21 | 0 |
Tangible Book Value Per Share | 0.77 | 0.93 | 0.45 | 0.03 | -0.00 | - |
Land | 41.9 | 41.9 | 41.9 | - | - | - |
Buildings | 18.12 | 18.12 | 18.12 | - | - | - |
Machinery | 21.66 | 15.05 | 6.42 | 5.88 | - | - |
Construction In Progress | 12.02 | 7.25 | 7.5 | - | - | - |
Leasehold Improvements | 0.91 | 0.91 | 0.91 | 0.91 | - | - |
Source: S&P Capital IQ. Standard template. Financial Sources.